Our Pipeline

Updated on January 30 2025.

Our determination to find answers for patients and their families motivates us to pursue medicines and vaccines with the greatest potential to improve lives and protect public health. With a strong focus on difficult-to-treat diseases and immunization, our R&D pipeline includes 83 clinical-stage projects, 33 of which are in phase 3 or have been submitted to regulatory authorities for approval. Some of these are new molecular entities while others are existing products with potential new indications, or different formulations. All of them are made possible by people who volunteer to participate in a clinical trial.

Phase 1
16
Phase 2
34
Phase 3
26
Registration
7

Changes that occurred in our R&D pipeline are detailed in our quarterly earnings press release, issued on 30 January 2025.

Search for a Specific Clinical-Stage Project

All therapeutic areas
All phases
All expected timeline
83 project(s) of 83
Therapeutic Area
Phase
Name
Description
Indication

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

SAR444336

Phase

1
2
3
R

Description

Non-beta IL2 Synthorin™

Indication

Inflammatory indication

Inflammatory indication

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

SAR445399

Phase

1
2
3
R

Description

IL1R3 mAb

Indication

Inflammatory indication

Inflammatory indication

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

SAR446422

Phase

1
2
3
R

Description

CD28xOX40 bispecific Ab

Indication

Inflammatory indication

Inflammatory indication

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

SAR446959

Phase

1
2
3
R

Description

MMP13xADAMTS5xCAP Nanobody® VHH
New

Indication

Knee osteoarthritis

New

Knee osteoarthritis

New

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

amlitelimab

Phase

1
2
3
R

Description

OX40L mAb

Indication

Celiac disease

Celiac disease

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

amlitelimab

Phase

1
2
3
R

Description

OX40L mAb

Indication

Systemic sclerosis

Systemic sclerosis

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

amlitelimab

Phase

1
2
3
R

Description

OX40L mAb

Indication

Alopecia areata

Alopecia areata

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

amlitelimab

Phase

1
2
3
R

Description

OX40L mAb

Indication

Hidradenitis suppurativa

Hidradenitis suppurativa

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

amlitelimab

Phase

1
2
3
R

Description

OX40L mAb

Indication

Asthma

Asthma

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

balinatunfib

Phase

1
2
3
R

Description

Oral TNFR1 signaling inhibitor
New phase

Indication

Crohn’s disease

New phase

Crohn’s disease

New phase

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

balinatunfib

Phase

1
2
3
R

Description

Oral TNFR1 signaling inhibitor

Indication

Rheumatoid arthritis

Rheumatoid arthritis

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

balinatunfib

Phase

1
2
3
R

Description

Oral TNFR1 signaling inhibitor

Indication

Psoriasis

Psoriasis

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

brivekimig

Phase

1
2
3
R

Description

TNFaxOX40L Nanobody® VHH

Indication

Hidradenitis suppurativa

Hidradenitis suppurativa

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

Dupixent

Phase

1
2
3
R

Description

IL4xIL13 mAb

Indication

Ulcerative colitis

Ulcerative colitis

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

duvakitug

Phase

1
2
3
R

Description

TL1A mAb

Indication

Crohn's disease

Crohn's disease

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

duvakitug

Phase

1
2
3
R

Description

TL1A mAb

Indication

Ulcerative colitis

Ulcerative colitis

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

eclitasertib

Phase

1
2
3
R

Description

RIPK1 inhibitor

Indication

Ulcerative colitis

Ulcerative colitis

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

frexalimab

Phase

1
2
3
R

Description

CD40L mAb

Indication

Type 1 diabetes

Type 1 diabetes

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

frexalimab

Phase

1
2
3
R

Description

CD40L mAb

Indication

Systemic lupus erythematosus

Systemic lupus erythematosus

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

itepekimab

Phase

1
2
3
R

Description

IL33 mAb

Indication

Bronchiectasis

Bronchiectasis

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

lunsekimig

Phase

1
2
3
R

Description

IL13xTSLP Nanobody® VHH
New phase

Indication

High-risk asthma

New phase

High-risk asthma

New phase

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

lunsekimig

Phase

1
2
3
R

Description

IL13xTSLP Nanobody® VHH

Indication

Chronic rhinosinusitis with nasal polyps

Chronic rhinosinusitis with nasal polyps

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

lunsekimig

Phase

1
2
3
R

Description

IL13xTSLP Nanobody® VHH

Indication

Asthma

Asthma

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

riliprubart

Phase

1
2
3
R

Description

C1s inhibitor

Indication

Antibody-mediated rejection

Antibody-mediated rejection

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

rilzabrutinib

Phase

1
2
3
R

Description

BTK inhibitor

Indication

Chronic spontaneous urticaria

Chronic spontaneous urticaria

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

rilzabrutinib

Phase

1
2
3
R

Description

BTK inhibitor

Indication

Asthma

Asthma

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

rilzabrutinib

Phase

1
2
3
R

Description

BTK inhibitor

Indication

IgG4-related disease

IgG4-related disease

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

SAR444656

Phase

1
2
3
R

Description

IRAK4 degrader

Indication

Hidradenitis suppurativa

Hidradenitis suppurativa

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

SAR444656

Phase

1
2
3
R

Description

IRAK4 degrader

Indication

Atopic dermatitis

Atopic dermatitis

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

amlitelimab

Phase

1
2
3
R

Description

OX40L mAb

Indication

Atopic dermatitis

Atopic dermatitis

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

Dupixent

Phase

1
2
3
R

Description

IL4xIL13 mAb
New phase

Indication

Lichen simplex chronicus

New phase

Lichen simplex chronicus

New phase

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

Dupixent

Phase

1
2
3
R

Description

IL4xIL13 mAb

Indication

Eosinophilic gastritis

Eosinophilic gastritis

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

Dupixent

Phase

1
2
3
R

Description

IL4xIL13 mAb

Indication

Bullous pemphigoid

Bullous pemphigoid

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

Dupixent

Phase

1
2
3
R

Description

IL4xIL13 mAb

Indication

Chronic pruritis of unknown origin

Chronic pruritis of unknown origin

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

itepekimab

Phase

1
2
3
R

Description

IL33 mAb

Indication

Chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

Rezurock

Phase

1
2
3
R

Description

ROCK2 inhibitor

Indication

Chronic graft versus host disease, 1L

Chronic graft versus host disease, 1L

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

Rezurock

Phase

1
2
3
R

Description

ROCK2 inhibitor

Indication

Chronic lung allograft dysfunction

Chronic lung allograft dysfunction

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

Tzield

Phase

1
2
3
R

Description

CD3 mAb

Indication

Type 1 diabetes

Type 1 diabetes

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

Dupixent

Phase

1
2
3
R

Description

IL4xIL13 mAb

Indication

Chronic obstructive pulmonary disease (JP)

Chronic obstructive pulmonary disease (JP)

Therapeutic Area

Immunology & Inflammation

1
2
3
R

Name

Dupixent

Phase

1
2
3
R

Description

IL4xIL13 mAb

Indication

Chronic spontaneous urticaria (US, EU)

Chronic spontaneous urticaria (US, EU)

Therapeutic Area

Neurology

1
2
3
R

Name

SAR446159

Phase

1
2
3
R

Description

SynucleinxIGF1R mAb

Indication

Parkinson's disease

Parkinson's disease

Therapeutic Area

Neurology

1
2
3
R

Name

frexalimab

Phase

1
2
3
R

Description

CD40L mAb

Indication

Non-relapsing secondary progressive MS

Non-relapsing secondary progressive MS

Therapeutic Area

Neurology

1
2
3
R

Name

frexalimab

Phase

1
2
3
R

Description

CD40L mAb

Indication

Relapsing multiple sclerosis

Relapsing multiple sclerosis

Therapeutic Area

Neurology

1
2
3
R

Name

riliprubart

Phase

1
2
3
R

Description

C1s inhibitor

Indication

IVIg-treated CIDP

IVIg-treated CIDP

Therapeutic Area

Neurology

1
2
3
R

Name

riliprubart

Phase

1
2
3
R

Description

C1s inhibitor

Indication

SOC-refractory CIDP

SOC-refractory CIDP

Therapeutic Area

Neurology

1
2
3
R

Name

tolebrutinib

Phase

1
2
3
R

Description

BTK inhibitor

Indication

Non-relapsing secondary progressive MS

Non-relapsing secondary progressive MS

Therapeutic Area

Neurology

1
2
3
R

Name

tolebrutinib

Phase

1
2
3
R

Description

BTK inhibitor

Indication

Primary progressive MS

Primary progressive MS

Therapeutic Area

Oncology

1
2
3
R

Name

SAR444881

Phase

1
2
3
R

Description

ILT2 mAb

Indication

Solid tumors

Solid tumors

Therapeutic Area

Oncology

1
2
3
R

Name

SAR445514

Phase

1
2
3
R

Description

Trifunctional anti-BCMA NK cell engager

Indication

Relapsed/refractory multiple myeloma

Relapsed/refractory multiple myeloma

Therapeutic Area

Oncology

1
2
3
R

Name

SAR445877

Phase

1
2
3
R

Description

PD1xIL-15 fusion protein

Indication

Solid tumors

Solid tumors

Therapeutic Area

Oncology

1
2
3
R

Name

SAR445953

Phase

1
2
3
R

Description

CEACAM5-Topo1 ADC

Indication

Colorectal cancer

Colorectal cancer

Therapeutic Area

Oncology

1
2
3
R

Name

SAR443579

Phase

1
2
3
R

Description

Trifunctional anti-CD123 NK cell engager

Indication

Acute myeloid leukemia

Acute myeloid leukemia

Therapeutic Area

Oncology

1
2
3
R

Name

SAR447873

Phase

1
2
3
R

Description

SSTR targeting alpha-emitter therapy
New

Indication

Gastroenteropancreatic neuroendocrine tumors

New

Gastroenteropancreatic neuroendocrine tumors

New

Therapeutic Area

Oncology

1
2
3
R

Name

Sarclisa

Phase

1
2
3
R

Description

CD38 mAb

Indication

Relapsed/refractory multiple myeloma

Relapsed/refractory multiple myeloma

Therapeutic Area

Oncology

1
2
3
R

Name

Sarclisa

Phase

1
2
3
R

Description

CD38 mAb

Indication

NDMM, TE (IsKia)

NDMM, TE (IsKia)

Therapeutic Area

Oncology

1
2
3
R

Name

Sarclisa

Phase

1
2
3
R

Description

CD38 mAb subcutaneous

Indication

Relapsed/refractory multiple myeloma (IRAKLIA)

Relapsed/refractory multiple myeloma (IRAKLIA)

Therapeutic Area

Oncology

1
2
3
R

Name

Sarclisa

Phase

1
2
3
R

Description

CD38 mAb

Indication

Smoldering multiple myeloma (ITHACA)

Smoldering multiple myeloma (ITHACA)

Therapeutic Area

Oncology

1
2
3
R

Name

Sarclisa

Phase

1
2
3
R

Description

CD38 mAb
New phase

Indication

NDMM, TE (HD7) (EU)

New phase

NDMM, TE (HD7) (EU)

New phase

Therapeutic Area

Oncology

1
2
3
R

Name

Sarclisa

Phase

1
2
3
R

Description

CD38 mAb

Indication

NDMM, TI (IMROZ) (JP)

NDMM, TI (IMROZ) (JP)

Therapeutic Area

Rare Diseases

1
2
3
R

Name

rilzabrutinib

Phase

1
2
3
R

Description

BTK inhibitor

Indication

Warm autoimmune hemolytic anemia

Warm autoimmune hemolytic anemia

Therapeutic Area

Rare Diseases

1
2
3
R

Name

SAR447537

Phase

1
2
3
R

Description

AAT fusion protein

Indication

Alpha-1 antitrypsin deficiency

Alpha-1 antitrypsin deficiency

Therapeutic Area

Rare Diseases

1
2
3
R

Name

Nexviazyme

Phase

1
2
3
R

Description

Enzyme replacement therapy

Indication

Pompe disease, infantile onset (US)

Pompe disease, infantile onset (US)

Therapeutic Area

Rare Diseases

1
2
3
R

Name

venglustat

Phase

1
2
3
R

Description

Oral GCS inhibitor

Indication

Fabry disease

Fabry disease

Therapeutic Area

Rare Diseases

1
2
3
R

Name

venglustat

Phase

1
2
3
R

Description

Oral GCS inhibitor

Indication

Gaucher disease type 3

Gaucher disease type 3

Therapeutic Area

Rare Diseases

1
2
3
R

Name

fitusiran

Phase

1
2
3
R

Description

RNAi targeting anti-thrombin

Indication

Hemophilia A and B (US, CN)

Hemophilia A and B (US, CN)

Therapeutic Area

Rare Diseases

1
2
3
R

Name

rilzabrutinib

Phase

1
2
3
R

Description

BTK inhibitor
New phase

Indication

Immune thrombocytopenia (US, EU, CN)

New phase

Immune thrombocytopenia (US, EU, CN)

New phase

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0237

Phase

1
2
3
R

Description

mRNA vaccine

Indication

Flu

Flu

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0256

Phase

1
2
3
R

Description

mRNA vaccine

Indication

RSV+hMPV (older adults)

RSV+hMPV (older adults)

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0268

Phase

1
2
3
R

Description

mRNA vaccine

Indication

Acne

Acne

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0287

Phase

1
2
3
R

Description

Flublok+Nuvaxovid
New

Indication

Flu+COVID-19

New

Flu+COVID-19

New

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0287

Phase

1
2
3
R

Description

Fluzone HD+Nuvaxovid
New

Indication

Flu+COVID-19

New

Flu+COVID-19

New

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0289

Phase

1
2
3
R

Description

mRNA vaccine
New

Indication

Flu (H5 pandemic)

New

Flu (H5 pandemic)

New

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0291

Phase

1
2
3
R

Description

mRNA vaccine
New

Indication

RSV+hMPV+PIV3 (older adults)

New

RSV+hMPV+PIV3 (older adults)

New

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0218

Phase

1
2
3
R

Description

Vero cell vaccine

Indication

Yellow fever

Yellow fever

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0230

Phase

1
2
3
R

Description

5-valent (ABCYW) vaccine

Indication

Meningitis

Meningitis

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0256

Phase

1
2
3
R

Description

mRNA vaccine

Indication

RSV (older adults)

RSV (older adults)

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0335

Phase

1
2
3
R

Description

Inactivated adjuvanted vaccine
New

Indication

Flu (H5 pandemic)

New

Flu (H5 pandemic)

New

Therapeutic Area

Vaccines

1
2
3
R

Name

Fluzone HD

Phase

1
2
3
R

Description

Multivalent inactivated vaccine
New phase

Indication

Flu (50 years+)

New phase

Flu (50 years+)

New phase

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0087

Phase

1
2
3
R

Description

Vero cell vaccine

Indication

Rabies

Rabies

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0125

Phase

1
2
3
R

Description

Live attenuated vaccine

Indication

RSV (toddlers)

RSV (toddlers)

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0202

Phase

1
2
3
R

Description

21-valent conjugate vaccine
New phase

Indication

Pneumococcal disease

New phase

Pneumococcal disease

New phase

Therapeutic Area

Vaccines

1
2
3
R

Name

SP0282

Phase

1
2
3
R

Description

9-valent conjugate vaccine

Indication

E. coli sepsis

E. coli sepsis

Therapeutic Area

Vaccines

1
2
3
R

Name

MenQuadfi

Phase

1
2
3
R

Description

4-valent (ACYW) conjugate vaccine
New phase

Indication

Meningitis (six weeks+) (US)

New phase

Meningitis (six weeks+) (US)

New phase

Related Links

Research & Development

See more

Technology Platforms

See more

Clinical trials & results

See more